Anlon Healthcare Limited was originally incorporated as 'Anlon Ventures Private Limited', a private limited company under the erstwhile Companies Act, 1956, pursuant to a certificate of incorporation dated November 19, 2013 issued by the RoC. The name of the company was changed from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited' and a fresh certificate of incorporation dated May 27, 2015 was issued by the RoC pursuant to the approval of the Board on May 1, 2015 and the Shareholders on May 5, 2015. The company was subsequently converted to a public limited company and the name of the company was changed from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited' pursuant to the approval of the Board dated July 8, 2024 and Shareholders on August 3, 2024 and a fresh certificate of incorporation dated September 2, 2024 was issued by the RoC.

The company is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates (Pharma Intermediate) which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients (APIs) which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula (FDF) such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products span across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. Its active pharmaceutical ingredient products are manufactured in accordance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, USP.

The company is one of the few manufacturers of loxoprofen sodium dihydrate in India, which is a notable API widely used in treatment of pain/inflammation association with conditions including rheumatoid arthritis, osteoarthritis, lower back pain, frozen shoulder, neck-shoulder-arm syndrome, tooth pain or after surgery, injury or tooth extraction. It is also engaged in custom API development, including the preparation and submission of regulatory Drug Master Files (DMFs) for Indian and global markets.

In addition to the manufacturing of Pharma Intermediate and APIs in accordance with various domestic and international standards, it has recently started undertaking custom manufacturing services for complex or novel chemical compounds, tailoring the manufacturing process to meet specific customer requirements, including producing chemicals with purity levels that exceed industry standards. Its domain knowledge and expertise enable it to reduce existing impurities and employ appropriate processes to achieve the desired level of purity.

Business area of the company

The company is a chemical manufacturing company engaged in manufacturing of pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs), which are supplied to customers both in India and international markets. Its products span across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API. It is also engaged in custom API development, including the preparation and submission of regulatory Drug Master Files (DMFs) for Indian and global markets.

Products of the company

• Pharmaceutical intermediates
• APIs
• Nutraceutical API
• Personal care products
• Animal health products

History and milestones

• 2013: Incorporated as 'Anlon Ventures Private Limited'.
• 2015: Change of name from 'Anlon Ventures Private Limited' to 'Anlon Healthcare Private Limited'.
• 2017: Received ISO 9001:2015 certification.
• 2018: Commenced commercial Production of Pharma Intermediate and API.
• 2018: Made its first export of its product to South Korea.
• 2018: Received Good Manufacturing Practice certification for its Manufacturing Facility from the Food & Drugs Control Administration (FDCA), Gujarat.
• 2018: Received accreditation of Foreign Manufacturer from Pharmaceuticals and Medical Devices Agency, Japan.
• 2021: Received Good Manufacturing Practice - World Health Organization Certification for its Manufacturing Facility.
• 2024: Received approval for Drug Master File from Brazilian Health Regulatory Agency for its API product namely, loxoprofen sodium dihydrate.
• 2024: Conversion of the company from private limited to public limited and the consequent change of name from 'Anlon Healthcare Private Limited' to 'Anlon Healthcare Limited'.